Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis
1
1
T.B. and B.M. received honoraria for advisory boards and lectures from Novartis and Pfizer. K.K. received honoraria for advisory boards and lectures from Novartis. Other authors have declared no conflict of interest. The RENIS registry is funded in part by pharmaceutical companies producing targeted agents for renal cancer (Pfizer, Bayer, GSK, Roche, and Novartis).
Titel:
Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis
1
1
T.B. and B.M. received honoraria for advisory boards and lectures from Novartis and Pfizer. K.K. received honoraria for advisory boards and lectures from Novartis. Other authors have declared no conflict of interest. The RENIS registry is funded in part by pharmaceutical companies producing targeted agents for renal cancer (Pfizer, Bayer, GSK, Roche, and Novartis).
Auteur:
Buchler, Tomas Bortlicek, Zbynek Poprach, Alexandr Kubackova, Katerina Kiss, Igor Zemanova, Milada Fiala, Ondrej Dusek, Ladislav Vyzula, Rostislav Melichar, Bohuslav